Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib vs Anagrelide in Essential Thrombocythemia (RESET-272)
NCT03123588Phase 2Terminated
- Sponsor
- Incyte
- Start
- Nov 2017
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ruxolitinib in essential thrombocythemia (ET) (2 arms), sponsored by Incyte. Primary endpoint: Proportion of Subjects Who Achieve Platelet and White Blood Cell (WBC) Control at 52 weeks. Started Nov 2017; status: terminated.
02
Drugs
03
Conditions
essential thrombocythemia (ET)
Beyond the preview
Go deeper on NCT03123588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03123588.